Several other research analysts also recently issued reports on the company. Cowen set a $1.00 price target on NantHealth and gave the stock a buy rating in a research note on Monday, August 26th. Zacks Investment Research lowered shares of NantHealth from a buy rating to a hold rating in a research report on Thursday, August 15th.
NH traded up $0.05 on Tuesday, hitting $1.08. 16,844 shares of the company were exchanged, compared to its average volume of 104,523. The business’s fifty day moving average is $0.74 and its 200 day moving average is $0.63. NantHealth has a fifty-two week low of $0.45 and a fifty-two week high of $1.96. The firm has a market capitalization of $96.24 million, a P/E ratio of -0.62 and a beta of 1.21.
NantHealth (NASDAQ:NH) last issued its earnings results on Thursday, November 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.08). NantHealth had a negative net margin of 105.82% and a negative return on equity of 10,106.10%. The company had revenue of $22.36 million during the quarter, compared to analysts’ expectations of $23.40 million. On average, sell-side analysts predict that NantHealth will post -0.46 earnings per share for the current fiscal year.
Institutional investors have recently modified their holdings of the business. Tower Research Capital LLC TRC lifted its holdings in shares of NantHealth by 778.8% during the 3rd quarter. Tower Research Capital LLC TRC now owns 45,988 shares of the company’s stock worth $33,000 after acquiring an additional 40,755 shares during the period. Miracle Mile Advisors LLC grew its holdings in NantHealth by 154.2% in the second quarter. Miracle Mile Advisors LLC now owns 75,000 shares of the company’s stock valued at $39,000 after purchasing an additional 45,500 shares during the period. Finally, Paloma Partners Management Co grew its holdings in NantHealth by 436.1% in the second quarter. Paloma Partners Management Co now owns 91,100 shares of the company’s stock valued at $48,000 after purchasing an additional 74,108 shares during the period. 3.27% of the stock is currently owned by institutional investors.
NantHealth, Inc, together with its subsidiaries, operates as a healthcare technology company in the United States and internationally. The company engages in converging science and technology through an integrated clinical platform to provide health information at the point of care. It develops NantHealth solutions, including molecular profiling solutions, software, and hardware systems infrastructure, which integrates patient data management, bioinformatics, and molecular medicine to enable value-based care and evidence-based clinical practice.
See Also: Gross Domestic Product (GDP)
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.